A Drug That Should Never Have Existed
In the late 1950s, a West German pharmaceutical company called Chemie Grünenthal released a new sedative it believed would change medicine. Thalidomide was marketed as a mild, safe sleeping pill — one that, unusually, seemed almost impossible to overdose on. Doctors quickly discovered it also calmed morning sickness in pregnant women. It spread fast. By the early 1960s, thalidomide was sold under dozens of brand names in more than 46 countries across Europe, Africa, Asia, and Latin America. It was celebrated. It was trusted. It was catastrophically wrong.
What followed was one of the worst pharmaceutical disasters in history. Thousands of babies were born with phocomelia — a condition where limbs fail to develop properly, leaving children with shortened or entirely absent arms and legs. Some were born with damage to internal organs, eyes, and ears. Estimates suggest around 10,000 children worldwide were affected. Roughly half did not survive infancy. The cause took time to identify, partly because no one initially suspected a drug so widely considered safe. By the time the connection was confirmed, thalidomide had already left a permanent mark on a generation.
The Woman Who Read Every Page
Frances Kathleen Oldham Kelsey was not a typical FDA reviewer, in the best possible sense. Born in Canada in 1914, she had earned both a doctorate in pharmacology and a medical degree, and had spent years doing serious scientific research. She joined the Food and Drug Administration in 1960, and thalidomide — submitted for US approval under the brand name Kevadon — was almost literally her first assignment.
What Kelsey found when she read the application troubled her immediately. The safety data was sparse and poorly constructed. There were no adequate studies on how the drug behaved in the human body over time. More specifically, there was almost no research on what happened when thalidomide crossed the placental barrier — the biological boundary between a mother's bloodstream and a developing fetus. To Kelsey, this was not a technicality. It was a fundamental gap in the science.
She also took notice of reports already emerging from Britain about peripheral neuritis — nerve damage in adults who used the drug long-term. If thalidomide was damaging nerves in grown adults, what might it be doing to a fetus during the most fragile weeks of development? The question kept her firm.
Twelve Rejections
The drug's American distributor, the William S. Merrell Company, was not patient. They contacted Kelsey repeatedly — by her own account, approximately twelve times — pressing her to approve the application. They questioned her judgment, complained to her supervisors, and treated her scientific caution as an obstruction rather than a professional responsibility. At one point, company representatives reportedly described her as being unreasonable and overly cautious to the point of incompetence.
Kelsey did not move. Each time she responded with the same demand: provide sufficient evidence of safety. The company could not, because the evidence did not exist.
By late 1961, a German paediatrician named Widukind Lenz had made the definitive connection between thalidomide and birth defects in Europe. The drug was withdrawn from the German market in November of that year. Merrell quietly withdrew its US application shortly after. Thalidomide was never approved in the United States.
Why It Changed Everything
The near-miss transformed American drug regulation permanently. In 1962, Congress passed the Kefauver-Harris Amendment, which fundamentally strengthened the FDA's authority. For the first time, drug manufacturers were required to prove not only that a drug was safe, but that it was effective — and to conduct proper clinical trials before approval. Informed patient consent became a legal requirement. The amendment is considered one of the most important pieces of health legislation in American history, and it exists in large part because of what Frances Kelsey refused to do.
President John F. Kennedy awarded her the President's Award for Distinguished Federal Civilian Service in 1962 — one of the highest honours available to a government employee. She continued working at the FDA for decades, becoming a quiet but powerful force in shaping how new drugs reached the public.
Frances Kelsey died in 2015 at the age of 101. She never described herself as a hero. She described herself as someone who simply read the paperwork carefully and asked for proof. In medicine, that turned out to be everything.
